Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB

Neither bebtelovimab nor any mAb combinations tested neutralized the SARS-CoV-2 omicron subvariants BQ.1.1 and XBB, but remdesivir, molnupiravir, and nirmatrelvir were efficacious against both in vitro.

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 388; no. 1; pp. 89 - 91
Main Authors Imai, Masaki, Ito, Mutsumi, Kiso, Maki, Yamayoshi, Seiya, Uraki, Ryuta, Fukushi, Shuetsu, Watanabe, Shinji, Suzuki, Tadaki, Maeda, Ken, Sakai-Tagawa, Yuko, Iwatsuki-Horimoto, Kiyoko, Halfmann, Peter J., Kawaoka, Yoshihiro
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 05.01.2023
Subjects
Antiviral agents
Antiviral Agents - pharmacology
Antiviral Agents - therapeutic use
Coronavirus
Coronaviruses
Correspondence
COVID-19
COVID-19 - virology
COVID-19 Drug Treatment
Disease transmission
Drugs
FDA approval
Humans
Infectious Disease
Infectious diseases
Medical research
Monoclonal antibodies
R&D
Research & development
RNA polymerase
SARS-CoV-2 - drug effects
Severe acute respiratory syndrome coronavirus 2
Treatment Outcome
Viral Infections
Japan
Online AccessGet full text

Cover

More Information
Summary:Neither bebtelovimab nor any mAb combinations tested neutralized the SARS-CoV-2 omicron subvariants BQ.1.1 and XBB, but remdesivir, molnupiravir, and nirmatrelvir were efficacious against both in vitro.
Bibliography:SourceType-Scholarly Journals-1
ObjectType-Correspondence-1
content type line 14
ObjectType-Article-2
content type line 23
Drs. Imai and Ito and Drs. Kiso and Yamayoshi contributed equally to this letter.
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMc2214302